Results 41 to 50 of about 52,744 (222)
Anatomical Sciences Education, EarlyView.Abstract Medical education must balance foundational science with clinical relevance. Increasing emphasis on standardized assessments has led to prioritization of “high‐yield” conditions—those most likely to be assessed. Subsequently, educators and students often prioritize these conditions.
Kathryn Veazey, Oheneba Boadum
wiley +1 more source
Concentric Needle Jitter in 97 Myasthenia Gravis Patients
Frontiers in Neurology, 2020 Objectives: To estimate the jitter parameters (single-fiber electromyography) in myasthenia gravis patients mostly by electrical activation in Frontalis, Orbicularis Oculi, and Extensor Digitorum muscles using a concentric needle electrode.Methods ...
João Aris Kouyoumdjian +2 more
doaj +1 more source
Clinical and functional studies of autoimmune disorders of neuromuscular transmission [PDF]
, 2015 Inherited and acquired disorders of the neuromuscular junction are an important cause of muscle weakness and fatigability. In this thesis I focus on the autoimmune disorders of neuromuscular transmission.
Spillane, J
core
British Journal of Clinical Pharmacology, EarlyView.Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley +1 more source
European Journal of Medical ResearchObjective To investigate the impact of SHP2 on thymic epithelial tumors (TETs) and its underlying mechanisms. Methods Bioinformatic analysis was performed to identify key pathways in TETs.
Congya Yan, Shuai Zhao, Guoyan Qi
doaj +1 more source
Clinical predictors for the prognosis of myasthenia gravis
BMC Neurology, 2017 Background Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified.
Lili Wang, Yun Zhang, Maolin He
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Pregnant and breastfeeding individuals are routinely excluded from clinical drug development, creating persistent evidence gaps in pharmacology, safety, and dosing. Despite mandatory contraception and pregnancy testing, unintended pregnancies occur, particularly during the development of central nervous system (CNS) medicines used by women of ...
Sam Schoenmakers +4 more
wiley +1 more source
Features of depression development in myasthenia gravis.
Medičnì Perspektivi, 2020 The relative risk of developing depression in myasthenia gravis is 2.14 times higher than in the general population. The features of depression in myasthenia patients remain poorly understood and need to be clarified.
O. I. Kalbus +4 more
doaj +1 more source
Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study. [PDF]
PLoS ONE, 2014 The mechanisms that underlie the development and maintenance of autoimmunity in myasthenia gravis are poorly understood. In this investigation, we evaluate the role of survivin, a member of the inhibitor of apoptosis protein family, in humans and in two ...
Linda L Kusner +4 more
doaj +1 more source
Next‐Generation CAR‐T Cell Therapy: From Modular Design to Clinical Expansion
Exploration, EarlyView.Over the past decades, chimeric antigen receptor (CAR)‐T cell therapy has evolved from a linear engineering concept into a powerful yet constrained immunotherapy, limited by tumour microenvironment barriers, immune evasion, and manufacturing complexity.
Yuesong Bai +5 more
wiley +1 more source